Extended-Spectrum ß-lactamase-producing enterobacteriaceae infections in children: A two-center case-case-control study of risk factors and outcomes in Chicago, Illinois

Journal of the Pediatric Infectious Diseases Society

Volumn 3, Issue 4, 2014, Pages 312-319

  Logan, Latania K ^a,c   Meltzer, Laura A ^a   McAuley, James B ^a,g   Hayden, Mary K ^a   Beck, Todd ^b   Braykov, Nikolay P ^d,h   Laxminarayan, Ramanan ^d,e,f   Weinstein, Robert A ^a,c  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Jr Hospital of Cook County   (United States)

^d Economics and Policy   (United States)

^e PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^f PRINCETON UNIVERSITY   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

Antibacterial agents; Child; Drug resistance; Enterobacteriaceae infections; Epidemiology; lactamases

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM; COTRIMOXAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; BRAIN DISEASE; BRAIN HEMORRHAGE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFANT; KLEBSIELLA; MALE; MORTALITY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NEUROLOGIC DISEASE; NEWBORN; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEUS; RISK FACTOR; SEPSIS;

EID: 84928896199     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu011     Document Type: Article

References (32)

1. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol 2013; 34:259-68.
2. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14.
3. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54:969-76.
4. Bush K, Fisher J. Epidemiological expansion, structural studies, and clinical challenges of new ß-lactamases from gram-negative bacteria. Annu Rev Microbiol 2011; 65:455-78.
5. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11:315-7.
6. Paterson DL, Bonomo RA. Extended-spectrum ß-lactamases: A clinical update. Clin Microbiol Rev 2005; 18:657-86.
7. Logan LK. Carbapenem-resistant Enterobacteriaceae: An emerging problem in children. Clin Infect Dis 2012; 55:852-9.
8. Stürenburg E, Mack D. Extended-spectrum ß-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47:273-95.
9. Shah AA, Hasan F, Ahmed S, Hameed A. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum ß-lactamases. ResMicrobiol 2004; 155:409-21.
10. Hayakawa K, Gattu S, Marchaim D, et al. Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum ß-lactamase in a large U.S. medical center. Antimicrob Agents Chemother 2013; 57:4010-8.
11. Stone PW, Gupta A, Loughrey M, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003; 24:601-6.
12. Apisarnthanarak A, Kiratisin P, Saifon P, et al. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: A case-case-control study. Am J Infect Control 2007; 35:606-12.
13. Ramphal R, Ambrose PG. Extended-spectrum ß-lactamases and clinical outcomes: Current data. Clin Infect Dis 2006; 42(suppl 4):S164-72.
14. Logan LK, Braykov NP, Weinstein RA, Laxminarayan R, for the CDC Epicenters Prevention Program. Extended-spectrum ß-lactamase-producing and third-generation cephalosporin-resistant Enterobacteriaceae in children: Trends in the United States, 1999-2011. J Pediatr Infect Dis Soc 2014; 3:320-8.
15. Blaschke AJ, Korgenski EK, Daly JA, et al. Extended-spectrum beta-lactamase-producing pathogens in a children's hospital: A 5-year experience. Am J Infect Control 2009; 37:435-41.
16. Jhaveri R, Bronstein D, Sollod J, Kitchen C, Krogstad P. Outcome of infections with extended spectrum beta-lactamase producing organisms in children. J Pediatr Infect Dis 2008; 3:229-33.
17. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115:942-9.
18. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: Addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005; 26:346-51.
19. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005; 51:211-7.
20. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement ( June 2010 Update). Wayne, PA: CLSI, December 29, 2011.
22. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
23. Centers for Disease Control and Prevention (CDC). The National Healthcare Safety Network (NHSN) Manual. Patient Safety Component Protocol. 2013; Available at: http://www.cdc. gov/nhsn/TOC_PSCManual.html (http://www.cdc.gov/nhsn/pdfs/ pscmanual/17pscnosinfdef_current.pdf). Accessed September 14, 2013.
24. Magiorakos A, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
25. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 2008; 68:108-15.
26. Hyle EP, Lipworth AD, Zaoutis TE, et al. Risk factors for increasing multidrug resistance among extended-spectrum betalactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis 2005; 40:1317-24.
27. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: Risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002; 23:254-60.
28. Blomberg B, Jureen R, Manji KP, et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 2005; 43:745-9.
29. Cantón R, Coque TM. The CTX-M ß-lactamase pandemic. Curr Opin Microbiol 2006; 9:466-75.
30. Munoz-Price LS, Quinn JP. The spread of Klebsiella pneumoniae carbapenemases: A tale of strains, plasmids, and transposons. Clin Infect Dis 2009; 49:1739-41.
31. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: High prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents 2010; 36:19-23.
32. Chandramohan L, Revell PA. Prevalence and molecular characterization of extended-spectrum-ß-lactamase-producing Enterobacteriaceae in a pediatric patient population. Antimicrob Agents Chemother 2012; 56:4765-70.